Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003128 · ClinicalTrials.gov registry record · Phase 3
Ifosfamide With or Without Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cancer of the Uterus
A Phase 3 study, sponsored by Gynecologic Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 166
- Enrollment target
NCT00003128 is a Phase 3 study that has completed, run by Gynecologic Oncology Group. The registered enrollment target is 166 participants.
The verdict
NCT00003128, a Phase 3 study, has completed, sponsored by Gynecologic Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 166 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether ifosfamide alone is more effective than ifosfamide plus paclitaxel in treating patients with cancer of the uterus. PURPOSE: Randomized phase III trial to compare the effectiveness of ifosfamide with or without paclitaxel in treating patients with advanced, refractory, or recurrent cancer of the uterus.
Interventions
- DRUG paclitaxel
- DRUG ifosfamide
- BIOLOGICAL filgrastim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 166 participants |
| Start Date | 1997-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003128
The ClinicalTrials.gov registry entry for NCT00003128 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 166 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gynecologic Oncology Group, which has 154 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which paclitaxel is the first listed.
NCT00003128 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003128 about?
NCT00003128 is a clinical study titled "Ifosfamide With or Without Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cancer of the Uterus". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether ifosfamide alone is more effective than ifosfamide plus paclitaxel in treating patients with cancer of the uterus. PURPOSE: Randomized phase III trial ...
What is the current status of trial NCT00003128?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 166 participants. The study started on 1997-11.
What interventions are being tested in trial NCT00003128?
The interventions under investigation include: paclitaxel (DRUG), ifosfamide (DRUG), filgrastim (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003128?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.